Analysis of 386 alternative medicinal products implicated in liver injury reveal clinically relevant associations with potentially hepatotoxic botanicals, pharmaceutical adulteration, heavy metal contamination, and undisclosed animal content
CAM-associated liver injury frequently manifests as ACLF with high mortality, driven by pervasive heavy metal contamination and adulteration. Unlabeled product exposure is a strong mortality predictor, highlighting the urgent need for mandatory product surveillance.
Authors
- Ajit K. Tharakan (ORCID: https://orcid.org/0000-0002-6430-2580)
- A. Grace Baby (ORCID: https://orcid.org/0009-0006-1469-9934)
- Rizwan Ahamed (ORCID: https://orcid.org/0000-0003-4747-6359)
- Arif Hussain Theruvath (ORCID: https://orcid.org/0000-0002-3570-3465)
- Philip Augustine (ORCID: https://orcid.org/0000-0003-0787-0984)
- Aryalakshmi Sreemohan (ORCID: https://orcid.org/0009-0004-6960-4627)
- Cyriac Abby Philips
- Tharun Tom Oommen
Institutions
- Rajagiri Hospital (IN)
Publication Details
- Journal
- Frontiers in Gastroenterology
- Published
- 2026-03-11
- DOI
- https://doi.org/10.3389/fgstr.2026.1784785
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00